Lavonas, Eric J. http://orcid.org/0000-0002-5891-1451
Burnham, Randy I.
Schwarz, John
Quackenbush, Eugenia
Lewis, Brandon
Rose, S. Rutherfoord
Greene, Spencer
Toschlog, Eric A.
Charlton, Nathan P.
Mullins, Michael E.
Schwartz, Richard
Denning, David
Sharma, Kapil
Kleinschmidt, Kurt
Bush, Sean P.
Anderson, Victoria E.
Ginde, Adit A.
Gerardo, Charles J.
Funding for this research was provided by:
BTG International, Inc.
Article History
Received: 12 April 2019
Revised: 23 July 2019
Accepted: 19 August 2019
First Online: 3 September 2019
Compliance with Ethical Standards
:
: This clinical trial and the subsequent subgroup analysis were funded by BTG International, Inc. In addition, the Denver Health and Hospital Authority (EJL, RJB, JS, and VJA) has research, consulting, and call center agreements with BTG International, Inc., and has completed research arrangements with the manufacturer of a competing antivenom. Duke University (CJG) has received research funding from BTG for projects beyond the current trial. Dr. Green has received income from BTG for professional consulting. No other author has received personal funds or has other conflicts to disclose.